TELA Bio (TELA) Investor presentation summary

Overview and opportunity

• Differentiated soft-tissue preservation and restoration approach; estimated US opportunity of $2.6B across hernia and abdominal wall reconstruction ($1.8B) and plastic and reconstructive surgery ($0.8B).

• US hernia market estimated at $1.8B annually; robotic procedures projected to rise from 14% in 2023 to 21% in 2027.

• Hernia market shift toward resorbable and reinforced tissue matrix solutions is supported by clinical evidence, robot compatibility, cost-effectiveness, and patient choice.

• US plastic and reconstructive surgery opportunity estimated at $800M; market includes uses such as head and neck, chest wall, pelvic, extremity, and breast reconstruction.

Portfolio and adoption

• OviTex portfolio includes Core, 1S, 2S, Low Profile, and Inguinal configurations, with layer counts and smooth surfaces tailored to placement and procedure needs.

• OviTex PRS combines ~95% biologic building block with ~5% synthetic reinforcement; polymer options include short-term resorbable, permanent, and long-term resorbable configurations.

• OviTex PRS is designed to manage fluid and control stretch direction; product features include tissue-regeneration macromolecules, embroidery patterns, and permeability elements.

• Since launch: ~90,000 OviTex implantations globally, ~20,000 OviTex PRS implantations in the US, 70+ published or presented works, and 1,500+ patients in peer-reviewed publications.

• Commercial access includes coverage at 5,000+ hospitals through GPO access; hernia repair has an established DRG-based reimbursement pathway.

Clinical evidence and market need

• BRAVO included 92 OviTex patients with 24-month follow-up; reported SSO incidence was 38% including SSI, SSI incidence 20.7%, and recurrence estimate 2.6%.

• BRAVO comparisons with other published studies are not head-to-head; differences in patient populations, surgeons, techniques, and other variables prevent direct comparison of results.

• A cited surgeon survey found 59% agreed permanent synthetic mesh use puts patients at long-term risk of complications; a company-sponsored poll found 3 of 4 hernia patients wanted proactive control in care.